Tobin S L, Chun N, Powell T M, McConnell L M
Stanford Program in Genomics, Ethics, and Society, Palo Alto, CA 94304, USA.
Genet Test. 1999;3(1):37-45. doi: 10.1089/gte.1999.3.37.
Two general classes of genes are associated with the development of Alzheimer disease (AD). The first group consists of genes that appear to cause AD when mutated, and the second category is composed of genes that are statistically associated with AD, depending on the inheritance of specific alleles. This paper reviews the current state of knowledge about the genetics of AD, and we then discuss the two molecular tests that are currently commercially available. These include a genetic test for mutations in the presenilin 1 (PS1) gene that can diagnose or predict a subset of early onset familial AD with a high degree of certainty. The value of the genetic test for the apolipoprotein (APOE) allele status is far less clear. Inheritance of the epsilon 4 allele is associated with an increased risk of AD at a population level, but APOE genotyping is inappropriate for prediction of future disease in an individual and offers only a marginal increase in diagnostic certainty when symptomatic individuals are tested. In the future, genetic tests may become more broadly applicable to the diagnosis and prediction of AD. However, the utility of such tests is currently limited to a small subset of individuals because in the vast majority of AD cases no clear genetic or environmental cause has been defined.
两类基因与阿尔茨海默病(AD)的发病相关。第一类基因是那些发生突变时似乎会引发AD的基因,第二类基因则是根据特定等位基因的遗传情况,在统计学上与AD相关联的基因。本文回顾了目前关于AD遗传学的知识现状,然后讨论了目前市面上两种可商业化的分子检测方法。其中包括针对早老素1(PS1)基因突变的基因检测,它能够高度准确地诊断或预测一部分早发型家族性AD。而针对载脂蛋白(APOE)等位基因状态的基因检测价值则远不那么明确。在人群层面,ε4等位基因的遗传与AD风险增加相关,但APOE基因分型不适用于预测个体未来的疾病,并且在对有症状个体进行检测时,其诊断确定性仅略有提高。未来,基因检测可能会更广泛地应用于AD的诊断和预测。然而,目前此类检测的效用仅限于一小部分个体,因为在绝大多数AD病例中,尚未明确其遗传或环境病因。